Compare Intel Corp (INTC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Repligen Corporation Common Stock — how do they compare? Intel Corp trades at $94.94 (market cap $543.46B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Intel Corp is far larger — about 48.8× Repligen Corporation Common Stock's market cap, and Intel Corp pays a 2.24% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Repligen Corporation Common Stock for 0 Days on average.
| INTC | RGEN | |
|---|---|---|
Market Cap | $543.46B | $11.14B |
Volume | 87,420,405 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $140.94 | $194.57 |
52-Week Low | $33.62 | $102.87 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $564.27B | $11.02B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $98.12, down 3.19% today, amid mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company shows improving operational trends with three consecutive quarterly EPS beats and positive operating cash flow of $9.70B in 2025, though net income remains negative at -$267M. The stock has surged over 220% year-to-date as investors assess the progress of Intel's foundry turnaround strategy and High-NA chipmaking advancements.
Intel presents a high-risk, high-reward opportunity as the company executes its strategic pivot to a foundry model. While valuation metrics appear stretched with a P/E of 904, analyst consensus targets $111.72 suggesting 14% upside potential. Key risks include intense competition from TSMC and AMD, ongoing negative profitability, and the execution challenges of the foundry transition in a capital-intensive industry.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
